Search Result

Results for "

glioblastoma (GBM)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (3) Antibiotic (1) Apoptosis (18) Bcl-2 Family (2) c-Myc (1) Caspase (8) CDK (1) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (1) DNA-PK (1) Dopamine Receptor (3) DYRK (1) EGFR (6) ERK (2) Estrogen Receptor/ERR (1) FAK (2) Ferroptosis (1) Fungal (1) Glycosidase (2) GSK-3 (1) Hedgehog (1) Histone Methyltransferase (1) HSP (2) IAP (1) Interleukin Related (1) JNK (1) Keap1-Nrf2 (1) LPL Receptor (1) MDM-2/p53 (1) Microtubule/Tubulin (6) MMP (2) Monoamine Oxidase (1) mTOR (3) NADPH Oxidase (1) Necroptosis (1) NF-κB (6) OLIG2 (1) P2X Receptor (1) p38 MAPK (4) Parasite (2) PKA (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (3) Reference Standards (2) RIP kinase (1) ROCK (1) SDCBP (1) SGK (1) Src (2) STAT (5) Survivin (2) TNF Receptor (1) VEGFR (1) WDR5 (1)
By Research Areas:	Cancer (60) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (8) Neurological Disease (13)

By Targets:

ADC Payload (1)

Akt (3)

Antibiotic (1)

Apoptosis (18)

Bcl-2 Family (2)

c-Myc (1)

Caspase (8)

CDK (1)

DNA Alkylator/Crosslinker (1)

DNA Methyltransferase (1)

DNA-PK (1)

Dopamine Receptor (3)

DYRK (1)

EGFR (6)

ERK (2)

Estrogen Receptor/ERR (1)

FAK (2)

Ferroptosis (1)

Fungal (1)

Glycosidase (2)

GSK-3 (1)

Hedgehog (1)

Histone Methyltransferase (1)

HSP (2)

IAP (1)

Interleukin Related (1)

JNK (1)

Keap1-Nrf2 (1)

LPL Receptor (1)

MDM-2/p53 (1)

Microtubule/Tubulin (6)

MMP (2)

Monoamine Oxidase (1)

mTOR (3)

NADPH Oxidase (1)

Necroptosis (1)

NF-κB (6)

OLIG2 (1)

P2X Receptor (1)

p38 MAPK (4)

Parasite (2)

PKA (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (2)

RIP kinase (1)

ROCK (1)

SDCBP (1)

SGK (1)

Src (2)

STAT (5)

Survivin (2)

TNF Receptor (1)

VEGFR (1)

WDR5 (1)

By Research Areas:

Cancer (60)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (8)

Neurological Disease (13)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124813

PDZ1i 113B7	FAK EGFR MMP NF-κB SDCBP	Cancer
PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .

HY-122910

RIPGBM	Apoptosis	Cancer
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC₅₀ of ≤500 nM .

HY-118545

Butamirate	STAT	Inflammation/Immunology Cancer
Butamirate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate can be used for the study of glioblastoma .

HY-125427

SKOG102	OLIG2	Cancer
SKOG102 is a potent OLIG2 inhibitor that is directly engaging OLIG2 and interferes with the ability of OLIG2 to bind DNA. SKOG102 can be used for the research of glioblastoma (GBM) .

HY-170778

Tubulin polymerization-IN-77	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-77 (Compound 15c) is a tubulin polymerization inhibitor that exerts anti-glioblastoma activity by inhibiting tubulin polymerization. Tubulin polymerization-IN-77 demonstrates significant blood-brain barrier permeability, effectively inducing G2/M phase arrest and triggering apoptosis in GBM cells, while also significantly inhibiting tumor cell migration .

HY-161946

GBM CSCs-IN-1	Apoptosis	Cancer
GBM CSCs-IN-1 (Compound (−)-20), a derivative of rocaglate, is a potent inhibitor of glioblastoma stem cells (GBM CSCs) with an EC₅₀ of 45 nM, functioning by targeting the RNA helicase DDX3. Furthermore, GBM CSCs-IN-1 is also capable of inducing apoptosis .

HY-147789

FPDT	Akt	Neurological Disease Cancer
FPDT is an anti-glioblastoma agent. FPDT displays the IC₅₀ value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .

HY-123903

Tanshindiol B	Quinone Reductase	Cancer
Tanshindiol B, a naphthaquinone diterpene, inhibits glioblastoma (GBM) growth by induction of noptosis (NQO1-dependent necrosis) .

HY-125964

LLP-3	Survivin	Cancer
LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM) .

HY-174338

GPER/Bcl-2-IN-1	Estrogen Receptor/ERR Bcl-2 Family	Neurological Disease Cancer
GPER/Bcl-2-IN-1 is a GPER/Bcl-2 inhibitor. GPER/Bcl-2-IN-1 can inhibit the proliferation and neurospheres formation of glioblastoma cells. GPER/Bcl-2-IN-1 can be used for the study of glioblastoma multiforme (GBM) .

HY-118545A

Butamirate citrate	STAT	Inflammation/Immunology Cancer
Butamirate citrate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate citrate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate citrate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate citrate can be used for the study of glioblastoma .

HY-164527

Si306	Src FAK EGFR	Cancer
Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-19345

Vacquinol-1 NSC13316	p38 MAPK	Cancer
Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .

HY-19345A

Vacquinol-1 dihydrochloride NSC13316 dihydrochloride	p38 MAPK	Cancer
Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .

HY-155532

10m/ZS44	Apoptosis	Cancer
10m/ZS44 is a blood-brain barrier-permeable Glioblastoma (GBM) inhibitor. 10m/ZS44 significantly inhibits GBM tumor growth in a mouse xenograft model. 10m/ZS44 also activates the SIRT1/p53-mediated apoptosis pathway, thereby inhibiting the proliferation of U251 cells .

HY-12616

ACT-209905	LPL Receptor	Cancer
ACT-209905 is a S1P1 receptor agonist. ACT-209905 can inhibit glioblastoma (GBM) cell growth and migration. ACT-209905 also has immunomodulating activity, and can be used in research of autoimmune diseases .

HY-17595

Mebendazole 5 Publications Verification	Parasite Apoptosis Microtubule/Tubulin	Infection Cancer
Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .

HY-161256

Tubulin inhibitor 41	Microtubule/Tubulin Apoptosis	Cancer
Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells .

HY-149374

Tubulin inhibitor 36	Microtubule/Tubulin	Cancer
Tubulin inhibitor 36 (Compound 10) is a novel and potent tubulin inhibitor and inhibits the polymerization of microtubular protein then induces apoptosis with an IC₅₀ value of 1.5±0.1 μM. Tubulin inhibitor 36 (Compound 10) has significant anti-mitotic effect and exhibits activities against glioblastoma cells. Tubulin inhibitor 36 (Compound 10) has anti-tumor effects and can be used for glioblastoma multiforme (GBM) research .

HY-118545AR

Butamirate citrate (Standard)	Reference Standards STAT	Inflammation/Immunology Cancer
Butamirate citrate (Standard) is the analytical standard of Butamirate citrate (HY-118545A). This product is intended for research and analytical applications. Butamirate citrate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate citrate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate citrate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate citrate can be used for the study of glioblastoma .

HY-101349

L 741742	Dopamine Receptor Apoptosis	Neurological Disease Cancer
L 741742 is a dopamine receptor D4 (DRD4) antagonist that selectively inhibits glioblastomas (GBM) growth in vitro and in vivo, synergyed with Temozolomide (TMZ) (HY-17364). L 741742 disrupts in effectors PDGFRβ/ERK1/2 and mTOR signaling. Additionally, L 741742 disrupts endolysosmal function compromising the autophagy-lysosomal degradation pathway, followed by G0/G1 cell cycle arrest and Apoptosis. L 741742 is promising for research of GBM and neurogenesis .

HY-111452

EGFR-IN-85	EGFR	Cancer
EGFR-IN-85 (Compound 1) is an EGFR inhibitor. EGFR-IN-85 has IC₅₀ value of 0.19 μM for EGFRvⅢ phosphorylation. EGFR-IN-85 can suppress EGFR signaling within tumors. EGFR-IN-85 can be used for Glioblastoma (GBM) research .

HY-175754

C3TD078	WDR5	Cancer
C3TD078 is a WDR5 WIN site inhibitor with a K_i of 0.03  nM. C3TD078 has potent antiproliferative activity and reduces the stem-cell frequency of cancer stem cells (CSCs). C3TD078 can be used for glioblastoma (GBM) research .

HY-111187

KX2-361 KX-02	Src Microtubule/Tubulin Apoptosis	Cancer
KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell .

HY-12456

Duocarmycin SA	Antibiotic ADC Payload DNA Alkylator/Crosslinker Necroptosis Apoptosis	Cancer
Duocarmycin SA is an orally active antitumor antibiotic with an IC₅₀ of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .

HY-175781

CHI3L1-IN-4	Glycosidase STAT	Cancer
CHI3L1-IN-4 (Compound 8) is a Chitinase-3-Like Protein 1 (CHI3L1) inhibitor with a K_d of 6.8  μM. CHI3L1-IN-4 significantly reduces glioblastoma (GBM) spheroids viability and attenuates phospho-STAT3 levels by disrupting CHI3L1 pathway. CHI3L1-IN-4 can be used for GBM research .

HY-103407A

PD 168568 dihydrochloride	Dopamine Receptor	Neurological Disease Cancer
PD 168568 dihydrochloride is a orally active and potent dopamine receptor D₄ (DRD₄) antagonist. PD 168568 dihydrochloride contains an isoindolinone and is selective for the D₄ receptor versus D₂ and D₃, with K_i values of 8.8, 1842, and 2682 nM, respectively. PD 168568 dihydrochloride can be used for glioblastoma (GBM) research .

HY-103407

PD 168568	Dopamine Receptor	Neurological Disease Cancer
PD 168568 is a orally active and potent dopamine receptor D₄ (DRD₄) antagonist. PD 168568 contains an isoindolinone and is selective for the D₄ receptor versus D₂ and D₃, with K_i values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research .

HY-112293

GW2974	EGFR	Cancer
GW2974 is a potent dual inhibitor of EGFR and HER2 with IC₅₀ value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the EGFR and HER2 and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .

HY-W750654

Adonixanthin (3S,3′R)-Adonixanthin	Akt ERK p38 MAPK MMP NADPH Oxidase Reactive Oxygen Species (ROS) Keap1-Nrf2	Neurological Disease Cancer
Adonixanthin ( (3S,3'R)-Adonixanthin), a carotenoid, is an orally active anti-oxidative and anti-carcinogenic agent. Adonixanthin shows an ability to suppress cell proliferation and migration in three types of glioblastoma cells Adonixanthin exerts cytoprotective effects against various types of damage and inhibits the increased production of ROS. Adonixanthin protects against light-induced cell damage through not only an anti-oxidative response but also through Nrf2 activation. Adonixanthin suppresses glioblastoma progression and adonixanthin improves blood-brain barrier hyper-permeability in an autologous blood ICH model. Adonixanthin can be used for the study of glioblastoma (GBM) and intracerebral hemorrhage (ICH) .

HY-17595R

Mebendazole (Standard)	Reference Standards Parasite Apoptosis Microtubule/Tubulin	Infection Cancer
Mebendazole (Standard) is the analytical standard of Mebendazole. This product is intended for research and analytical applications. Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .

HY-172659

6-Epi-ophiobolin G MHO7	Fungal Akt Apoptosis	Cancer
6-Epi-ophiobolin G (MHO7), a Marine-derived fungal metabolite, is a blood-brain barrier penetrated and orally active Akt inhibitor. 6-Epi-ophiobolin G (MHO7) inhibits GBM cell proliferation and promotes apoptosis. 6-Epi-ophiobolin G (MHO7) can be used in the research for glioblastoma .

HY-175299

Hedgehog IN-11	Hedgehog Apoptosis DNA Methyltransferase	Cancer
Hedgehog IN-11 is an orally active Hedgehog inhibitor. Hedgehog IN-11 downregulates the expression of O6-methylguanine-DNA methyltransferase (MGMT) to impair the Temozolomide (TMZ) (HY-17364) resistance by inhibiting the Hedgehog pathway. Hedgehog IN-11 shows improved inhibition of cell migration and invasion, and induced cell apoptosis in TMZ-resistant GBM cell lines. Hedgehog IN-11 is predicted by computer simulation to have good blood-brain barrier penetration. Hedgehog IN-11 can be used for the study of glioblastoma (GBM) .

HY-N3001

Isolinderalactone	STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase	Neurological Disease Inflammation/Immunology Cancer
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-114413

YZ129	HSP Apoptosis	Cancer
YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to heat shock protein 90 (HSP90) with an IC₅₀ of 820 nM on NFAT nuclear translocation. YZ129-induced GBM cell-cycle arrest at the G2/M phase promotes apoptosis and inhibited tumor cell proliferation and migration .

HY-150794

FLDP-8	Others	Cancer
FLDP-8 is a curcuminoid analogues, has potent anti-cancer effects. FLDP-8 can induce cell death with an IC₅₀ value of 4 μM in LN-18 cells .

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .

HY-19939S

VX-984 4 Publications Verification M9831	DNA-PK	Cancer
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-149696

IR-Crizotinib	NF-κB	Cancer
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC₅₀=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .

HY-14942A

Berubicin hydrochloride RTA 744; WP 744; WP 769 hydrochloride	NF-κB Apoptosis Caspase	Neurological Disease Cancer
Berubicin (RTA 744) hydrochloride is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin hydrochloride inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin hydrochloride exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin hydrochloride can be used in the study of tumors related to the nervous system .

HY-14942

Berubicin RTA 744 free base; WP 744 free base; WP 769	NF-κB Apoptosis Caspase	Neurological Disease Cancer
Berubicin (RTA 744 free base) is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin can be used in the study of tumors related to the nervous system .

HY-178499

CDK9-IN-44	CDK	Neurological Disease Cancer
CDK9-IN-44 (Compound 7) is a selective CDK9 inhibitor (IC₅₀=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders .

HY-115630

cRIPGBM chloride	RIP kinase Caspase Apoptosis	Cancer
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .

HY-172586

GSK-3α/β-IN-1	GSK-3 PKA	Neurological Disease Cancer
GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC₅₀s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC₅₀ of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC₅₀: 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM .

HY-175207

CHI3L1-IN-3	Glycosidase	Cancer
CHI3L1-IN-3 is a CHI3L1 inhibitor. CHI3L1-IN-3 binds to CHI3L1 with K_ds of 13.76 μM and 13.5 μM in MST and SPR assays, respectively. CHI3L1-IN-3 demonstrates extended plasma half-lives and microsomal stability, along with reduced intrinsic clearance. CHI3L1-IN-3 induces dose-dependent cytotoxicity, reduces spheroid mass and inhibits migration in a 3D multicellular glioblastoma (GBM) spheroid model. CHI3L1-IN-3 can be used for the study of GBM .

HY-174212

MXC-017	Apoptosis	Cancer
MXC-017 is a blood-brain barrier (BBB)-penetrant apoptosis inducer that directly targets Vimentin (VIM). MXC-017 prevents radiation-induced glioma stem cell (GSC) formation, while promoting G0/G1 cell cycle arrest and apoptosis. MXC-017 exhibits minimal off-target effects and shows no significant cytotoxicity. MXC-017 significantly prolongs median survival when used in combination with radiation therapy in glioblastoma (GBM) mouse models.

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

Cat. No.	Product Name	Type

HY-149696

IR-Crizotinib

Dyes

IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC₅₀=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P11029

CES	Peptides	Cancer
CES (CESPLLSEC) is a homing peptide targeting Synaptosomal associated protein 25 (SNAP25). CES specifically homes in intracranial U87MG and the WT-glioblastoma (GBM) model. CES can be used as a targeting peptide for drug delivery for cancers research .

Cat. No.	Product Name	Target	Research Area